Safety and Efficacy of BCMA-Targeted CAR-T Therapy for Relapsed/Refractory Multiple Myeloma

Study Overview
=================
Brief Summary
-----------------
This is a single arm study to evaluate the efficacy and safety of BCMA-targeted CAR-T cells therapy for patients with relapsed/refractory Multiple Myeloma.

Detailed Description
-----------------
There are limited options for treatment of relapse/refractory Multiple Myeloma. BCMA is expressed on most Multiple Myeloma cells so it is an ideal target for CAR-T. In this study, investigators will evaluate the safety and efficacy of CAR-T targeting BCMA in patients with relapsed/refractory Multiple Myeloma. The primary goal is safety and efficiency assessment, including adverse events and disease status after treatment.

Official Title
-----------------
Safety and Efficacy of BCMA-Targeted CAR-T Therapy for Relapsed/Refractory Multiple Myeloma

Conditions
-----------------
Multiple Myeloma, Multiple Myeloma in Relapse, Neoplasm, Plasma Cell

Intervention / Treatment
-----------------
* Biological: BCMA CAR-T cells


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Signed written informed consent Diagnose as relapsed /refractory multiple myeloma, and meet one of the following conditions: Failed to standard chemotherapy regimens; Relapse after complete remission, high-risk and / or refractory patients ; Relapse after hematopoietic stem cell transplantation; Evidence for cell membrane BCMA expression； All genders, ages: 18 to 75 years； The expect time of survive is above 12 weeks; KPS>60； No serious mental disorders ; Left ventricular ejection fraction ≥50% Sufficient hepatic function defined by ALT/AST≤3 x ULN and bilirubin≤2 x ULN; Sufficient renal function defined by creatinine clearance≤2 x ULN; Sufficient pulmonary function defined by indoor oxygen saturation≥92%; With single or venous blood collection standards, and no other cell collection contraindications; Ability and willingness to adhere to the study visit schedule and all protocol requirements. Exclusion Criteria: Have received CAR-T therapy or other genetically modified cell therapy before screening； Participated in other clinical research within 1 month before screening； Have received the following anti-tumor treatment before screening: Have received chemotherapy, targeted therapy or other experimental drug treatment within 4 weeks, except those who have confirmed disease progression after treatment; Live attenuated vaccine within 4 weeks before screening; Convulsion or stoke within past 6 months; Previous history of other malignancy; Presence of uncontrolled active infection; Subjects with positive HBsAg or HBcAb positive and peripheral blood HBV DNA titer is higher than the lower limit of detection of the research institution; HCV antibody positive and peripheral blood HCV RNA titer is higher than the lower limit of detection of the research institution; HIV antibody positive; syphilis primary screening antibody positive; Pregnant or breasting-feeding women; Any situation that investigators regard not suitable for attending in this study or may affect the data analysis.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: BCMA CAR-T cells treat<br>Patients will be be treated with BCMA CAR-T cells | Biological: BCMA CAR-T cells<br>* A single infusion of BCMA CAR-T cells will be administered intravenously.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Adverse events that related to treatment | Therapy-related adverse events will be recorded and assessed according to the National Cancer Institute's Common Terminology Criteria for Adverse Events (CTCAE, Version 5.0) | 2 years | 
| The response rate of BCMA CAR-T treatment in patients with relapse/refractory Multiple Myeloma that treatment by BCMA CAR-T cells therapy | The response rate of BCMA CAR-T treatment will be recorded and assessed according to the IMWG | 6 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Rate of BCMA CAR-T cells in bone marrow and peripheral blood | In vivo (bone marrow and peripheral blood) rate of BCMA CAR-T cells were determined by means of flow cytometry | 2 years | 
| Quantity of BCMA CAR copies in bone marrow and peripheral blood | In vivo (bone marrow and peripheral blood) quantity of BCMA CAR copies were determined by means of qPCR | 2 years | 
| Quantity of clonal plasma cells in bone marrow | In vivo (bone marrow) quantity of clonal plasma cells | 1 years | 
| Levels of IL-6 in Serum | In vivo (Serum) quantity of IL-6 | 3 months | 
| Duration of Response (DOR) of BCMA CAR-T treatment in patients with refractory/relapsed Multiple Myeloma | DOR will be assessed from the first assessment of sCR/CR/VGPR/PR to the first assessment of recurrence or progression of the disease or death from any cause (censored) | 2 years | 
| Progress-free survival(PFS) of BCMA CAR-T treatment in patients with refractory/relapsed multiple myeloma | PFS will be assessed from the first CAR-T cell infusion to death from any cause or the first assessment of progression (censored) | 2 years | 
| Overall survival(OS) of BCMA CAR-T treatment in patients with refractory/relapsed multiple myeloma | OS will be assessed from the first CAR-T cell infusion to death from any cause (censored) | 2 years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Multiple Myeloma, Chimeric Antigen Receptor T cell, BCMA